United Therapeutics Corporation
587.50USD
+2.7100 (+0.46%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on UTHR.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $6.05▼ | $7 | 1 | 2 |
| Next quarter | $7.32▲ | $7.05 | 3 | 0 |
| Current year | $26.53▼ | $26.92 | 3 | 1 |
| Next year | $31.02▼ | $31.51 | 4 | 1 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $6.86 | $7.27 | +0.41 (+5.9%) |
| 2026-03-31 | $6.86 | $5.82 | -1.04 (-15.1%) |
| 2025-12-31 | $6.76 | $7.7 | +0.94 (+14.0%) |
| 2025-09-30 | $6.96 | $7.16 | +0.20 (+2.9%) |
194 ratings from 26 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| RBC Capital | Maintained | Outperform | $708 $697 | Oct 22, 2026 |
| Leerink Partners | Maintained | Outperform | $685 $725 | Oct 19, 2026 |
| RBC Capital | Maintained | Outperform | $677 $708 | Oct 8, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $515 $566 | Oct 7, 2026 |
| BTIG | Upgraded from Neutral | Buy | $728 | Oct 1, 2026 |
| Goldman Sachs | Initiated | Sell | $321 | Sep 24, 2026 |
| RBC Capital | Maintained | Outperform | $704 $677 | Aug 6, 2026 |
| JP Morgan | Maintained | Overweight | $685 $687 | Jul 23, 2026 |
| B of A Securities | Maintained | Neutral | $620 $613 | Jul 10, 2026 |
| RBC Capital | Maintained | Outperform | $701 $704 | Jul 7, 2026 |
| RBC Capital | Maintained | Outperform | $707 $701 | May 7, 2026 |
| Wells Fargo | Upgraded from Equal-Weight | Overweight | $575 $738 | May 7, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $471 $519 | Apr 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $600 $660 | Mar 31, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $486 $575 | Mar 31, 2026 |
| B of A Securities | Maintained | Neutral | $569 $626 | Mar 31, 2026 |
| TD Cowen | Maintained | Buy | $575 $660 | Mar 30, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $466 $486 | Mar 23, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $525 $625 | Mar 12, 2026 |
| UBS | Maintained | Buy | $655 $705 | Mar 5, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $525 $600 | Feb 26, 2026 |
| TD Cowen | Maintained | Buy | $525 $575 | Feb 26, 2026 |
| Oppenheimer | Maintained | Outperform | $575 $600 | Feb 26, 2026 |
| RBC Capital | Maintained | Outperform | $587 $643 | Feb 26, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $423 $466 | Feb 26, 2026 |
517 filings from 9 insiders · 156 buy / 151 sell over 6m
Officers and directors of UTHR, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | ExerciseindirectStock Option | 9.5k | — | — | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 160 | $590.40 | $94k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 240 | $589.50 | $141k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 783 | $588.19 | $461k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 937 | $587.24 | $550k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 1.3k | $586.31 | $750k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 1.8k | $585.24 | $1.03M | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 1.2k | $584.21 | $701k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 760 | $583.09 | $443k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 400 | $581.83 | $233k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 360 | $581.03 | $209k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 160 | $579.69 | $93k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 160 | $578.59 | $93k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 280 | $577.28 | $162k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 190 | $576.80 | $110k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 130 | $575.32 | $75k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Exerciseindirect | 9.5k | $117.76 | $1.12M | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 74 | $562.97 | $42k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 110 | $563.98 | $62k | Oct 22, 2026 |
| ROTHBLATT MARTINE ADirector; Officer, Chairperson & CEO | Sellindirect | 160 | $565.09 | $90k | Oct 22, 2026 |
No analyst notes on UTHR yet.
Analyst Ratings
14 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 8 | 3 | 1 | 0 | Buy2.13 |
| 1 mo ago | 3 | 8 | 3 | 1 | 0 | Buy2.13 |
| 2 mo ago | 3 | 8 | 3 | 0 | 0 | Buy2.00 |
| 3 mo ago | 3 | 9 | 3 | 0 | 0 | Buy2.00 |
Members whose judged calls on UTHR have played out most reliably.
No settled calls on UTHR yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice